ÀÖ²¥´«Ã½app×îа汾

In 2025, the Rapid Diagnostics category within Abbott Laboratories' diagnostics segment generated nearly 2.5 billion U.S. dollars, a significant decrease from the preceding years. The extraordinary growth witnessed in this segment was in large part an increased demand for COVID-19 tests since the beginning of the pandemic.